Leukemia, Myelodysplasia, Transplantation
News
NSAIDs can target LSCs in AML
Credit: Robert Paulson Preclinical research suggests that non-steroidal anti-inflammatory drugs (NSAIDs) might help prevent relapse in acute...
News
Gemtuzumab-ozogamicin improves event-free survival in pediatric AML
Key clinical point: In children, adolescents, and young adults with AML, the addition of gemtuzumab-ozogamicin (GO) to standard chemotherapy...
News
Study reveals why HSCs falter with age
A new study helps explain how blood production declines with age and why older individuals are not suitable donors for hematopoietic stem cell (...
News
Team pinpoints possible target for T-ALL
Researchers have discovered a potential therapeutic target for T-cell acute lymphoblastic leukemia (T-ALL), according to a paper published in Cell...
Clinical Review
Myelodysplastic Syndromes
News
Obinutuzumab approved for CLL in Europe
Obinutuzumab can now be used in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL) who...
News
FDA expands approved use of ibrutinib in CLL
Credit: Steven Harbour The US Food and Drug Administration (FDA) has expanded the approved use of ibrutinib (Imbruvica) in patients with chronic...
News
Healthy habits can cut risk of metabolic syndrome in childhood cancer survivors
patient and her father Credit: Rhoda Baer Following a healthy lifestyle can decrease the risk of metabolic syndrome in childhood cancer survivors...
News
CHMP recommends ibrutinib for CLL, MCL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is recommending marketing authorization for ibrutinib (...
News
CHMP recommends idelalisib for CLL, FL
Days after gaining approval for 3 indications in the US, idelalisib (Zydelig) has earned a positive opinion from the European Medicine Agency’s...
News
FDA approves idelalisib for CLL, SLL and FL
The drug was granted traditional approval for use in combination with rituximab to treat patients with relapsed CLL who cannot receive rituximab...